Jeremy Duffield, MD, PhD, FRCP, is the Chief Scientific Officer of Prime Medicine. He has many years of drug discovery experience at Vertex Pharmaceuticals and Biogen Inc. preceded by a distinguished career in academic medicine.
Dr. Duffield has held several leadership roles, with focus in the fields of human genetics, innate immunity, and regenerative medicine. He served as Global Head of Human Biology at Vertex Pharmaceuticals and as Vice President of Business Development where he and his team played important roles in discovering and advancing candidates to clinical studies in rare diseases including cystic fibrosis, a1-antitrypsin deficiency, sickle cell disease, FSGS and muscular dystrophies. Several candidates are now approved therapies. He was instrumental in building Vertex Cell and Genetic Therapies.
At Biogen, Dr. Duffield served as Senior Research Fellow and Vice President with responsibilities in early research programs, as joint Head of Innate Immunity and Regenerative Medicine therapeutic area, and as Head of the Biogen Post-Doctoral program. There he contributed to advancing integrin inhibitors, TNF superfamily inhibitors and IRAK inhibitors to clinical evaluation for pulmonary fibrosis and autoimmune diseases.
Prior to joining the leadership at Biogen, Dr. Duffield had a distinguished academic career on the faculty at University of Washington and Harvard Medical School as Head of the National Institutes of Health/National Center for Advancing Translational Sciences/American Heart Association-funded Laboratory for Innate Immunity and Regeneration. His laboratory used contemporary genetic methods to study cell and molecular function in innate immune and vascular cells in disease. Inventions from the laboratory contributed to the creation of several biotech companies, two of which advanced candidates now in late clinical trials. Additionally, Dr. Duffield practiced Internal Medicine and Nephrology at Massachusetts General Hospital until 2019.
Dr. Duffield served on NIH study sections, several company scientific advisory boards, is a member of the American Society of Clinical Investigation and received many scientific awards including the ASN-AHA Young Investigator Award and the NIH Early Career Investigator/Scholar Award.
Dr. Duffield received his B.A. and M.D. (B.M., B.Ch.) from Oxford University and a Ph.D. in Immunology from the University of Edinburgh in the laboratory of Sir John Savill.
Dr. Duffield has held several leadership roles, with focus in the fields of human genetics, innate immunity, and regenerative medicine. He served as Global Head of Human Biology at Vertex Pharmaceuticals and as Vice President of Business Development where he and his team played important roles in discovering and advancing candidates to clinical studies in rare diseases including cystic fibrosis, a1-antitrypsin deficiency, sickle cell disease, FSGS and muscular dystrophies. Several candidates are now approved therapies. He was instrumental in building Vertex Cell and Genetic Therapies.
At Biogen, Dr. Duffield served as Senior Research Fellow and Vice President with responsibilities in early research programs, as joint Head of Innate Immunity and Regenerative Medicine therapeutic area, and as Head of the Biogen Post-Doctoral program. There he contributed to advancing integrin inhibitors, TNF superfamily inhibitors and IRAK inhibitors to clinical evaluation for pulmonary fibrosis and autoimmune diseases.
Prior to joining the leadership at Biogen, Dr. Duffield had a distinguished academic career on the faculty at University of Washington and Harvard Medical School as Head of the National Institutes of Health/National Center for Advancing Translational Sciences/American Heart Association-funded Laboratory for Innate Immunity and Regeneration. His laboratory used contemporary genetic methods to study cell and molecular function in innate immune and vascular cells in disease. Inventions from the laboratory contributed to the creation of several biotech companies, two of which advanced candidates now in late clinical trials. Additionally, Dr. Duffield practiced Internal Medicine and Nephrology at Massachusetts General Hospital until 2019.
Dr. Duffield served on NIH study sections, several company scientific advisory boards, is a member of the American Society of Clinical Investigation and received many scientific awards including the ASN-AHA Young Investigator Award and the NIH Early Career Investigator/Scholar Award.
Dr. Duffield received his B.A. and M.D. (B.M., B.Ch.) from Oxford University and a Ph.D. in Immunology from the University of Edinburgh in the laboratory of Sir John Savill.
Speaking In
9:00 AM - 10:00 AM
Thursday, June 8
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
